ReviewCytotherapy2011
Tumor vaccines and beyond.
Review in Cytotherapy, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Current Development of Therapeutic Vaccines in Lung Cancer.Vaccines · 2025Review
- Therapeutic targets and biomarkers of tumor immunotherapy: response versus non-response.Signal transduction and targeted therapy · 2022Review
- Clinically feasible approaches to potentiating cancer cell-based immunotherapies.Human vaccines & immunotherapeutics · 2015Review
- Timing and intensity of exposure to interferon-γ critically determines the function of monocyte-derived dendritic cells.Immunology · 2014Article
- Expression of the brother of the regulator of imprinted sites gene in the sputum of patients with lung cancer.The Korean journal of thoracic and cardiovascular surgery · 2014Article
- Examining T cells at vaccine sites of tumor-bearing hosts provides insights to dysfunctional T-cell immunity.Journal of immunotherapy (Hagerstown, Md. : 1997) · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
For the last two decades the immunotherapy of patients with solid and hematopoietic tumors has met with variable success. We have reviewed the field of tumor vaccines to examine what has worked and what has not, why this has been the case, how the anti-tumor responses were examined, and how we can make tumor immunity successful for the majority of individuals rather than for the exceptional patients who currently show successful immune responses against their tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.